Company news

Correvio Pharma Corp news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cardiome Reports First Quarter 2017 Financial Results

May 15, 2017

Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds

May 15, 2017

Cardiome To Hold First Quarter 2017 Financial Results Conference Call On May 15

May 8, 2017

Cardiome to Present at the Bloom Burton & Co. 6th Annual Healthcare Investor Conference

April 27, 2017

Cardiome's Partner SteadyMed Announces Successful Completion of Trevyent® Clinical Validation Study

April 6, 2017

Cardiome's Partner SteadyMed Receives Favourable Ruling in its USPTO Inter Partes Review

April 3, 2017

Cardiome Receives Notice of Compliance from Health Canada for its BRINAVESS NDS

March 14, 2017

Cardiome Reports Fourth Quarter and Full Year 2016 Financial Results

March 7, 2017

Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France

March 3, 2017

Cardiome To Hold Fourth Quarter And Full Year 2016 Financial Results Conference Call On March 7

February 27, 2017

Cardiome Announces Commercial Launch of XYDALBA(TM) (dalbavancin) in Germany

December 20, 2016

Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK

December 8, 2016

Cardiome Advances Toward the UK XYDALBA(TM) (dalbavancin) Launch

November 29, 2016

Cardiome Reports Third Quarter 2016 Financial Results

November 7, 2016

Cardiome to Reschedule Release of Third Quarter 2016 Financial Results

November 1, 2016

Cardiome to Hold Third Quarter 2016 Financial Results Conference Call on November 7

October 28, 2016

Cardiome Announces Initiation of Commercial Operations in Canada, Eh

October 14, 2016

Cardiome Announces Recent Insider Purchases

August 16, 2016

Cardiome Reports Second Quarter 2016 Financial Results

August 9, 2016

Cardiome Announces XYDALBA(TM) Single Dose Infusion Approval by European Medicines Agency

August 9, 2016

Cardiome Announces the Addition of Two Key Members to its Management Team

August 8, 2016

Cardiome to Hold Second Quarter 2016 Financial Results Conference Call on August 9

August 3, 2016

Cardiome Closes Public Offering of 11,500,000 Common Shares

July 29, 2016

Cardiome Announces Pricing of Public Offering of 10,000,000 Common Shares

July 26, 2016

Cardiome Announces Proposed Public Offering of Common Shares

July 25, 2016

ESMOCARD® and ESMOCARD LYO® receive pricing approval and reimbursement in Italy

July 14, 2016

Cardiome Announces Term Loan Agreement with CRG-Managed Funds

June 14, 2016

Cardiome Reports First Quarter 2016 Financial Results

May 13, 2016

Cardiome Announces the Launch of ESMOCARD Solution for Injection in France

May 12, 2016

Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13

May 11, 2016

Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study

May 11, 2016

Cardiome and Allergan Announce XYDALBA(TM) (Dalbavancin) Licensing Agreement in International Markets

May 5, 2016

Cardiome to Present at the Bloom Burton & Co. 5th Annual Healthcare Investor Conference

April 28, 2016

Cardiome Announces Publication of Independent Study Comparing BRINAVESS to Ibutilide in Patients with Recent-Onset Atrial Fibrillation

March 31, 2016

Cardiome Reports Fourth Quarter and Full Year 2015 Financial Results

March 10, 2016

Cardiome Announces Filing of Prospectus Supplements

March 7, 2016

Cardiome To Hold Fourth Quarter And Full Year 2015 Financial Results Conference Call On March 10

March 4, 2016

Cardiome announces filing of shelf prospectus and registration statement

February 19, 2016

Cardiome To Present At The 5th Annual Leerink Partners Global Healthcare Conference

February 10, 2016

Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA

January 27, 2016

Cardiome Announces the Launch of ESMOCARD LYO in Belgium

January 21, 2016

Cardiome announces filing of marketing authorization application for intravenous vernakalant in the Kingdom Of Saudi Arabia

January 13, 2016

Cardiome Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC

January 12, 2016

Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency

January 6, 2016

Cardiome Enters Commercialization Agreement with Chong Kun Dang for BRINAVESS® in South Korea

January 5, 2016

Cardiome Files New Drug Submission Seeking Canadian Approval of intravenous vernakalant

December 22, 2015

Cardiome Reports Third Quarter 2015 Financial Results

November 13, 2015

Cardiome to Hold Third Quarter 2015 Financial Results Conference Call on November 13

November 6, 2015

Cardiome announces addition of Robert James Meyer, M.D. to board of directors

September 8, 2015

Cardiome to Present at the 17th Annual Rodman & Renshaw Global Investment Conference

August 27, 2015

← Newer news releases · Older news releases →

Decks